Given the aggressive nature of MPAL with BCR::ABL1 fusion, early diagnosis and targeted therapy with TKIs are critical. Looking ahead, the integration of novel tools such as digital pathology platforms and machine learning algorithms may enhance the early detection of genomic abnormalities and assist in predicting treatment responses, potentially reducing turnaround times and accelerating the initiation of tailored therapies. This evidence concerns the gene ABL1 and mixed phenotype acute leukemia.